| Autor: |
Tralongo AC; Medical Oncology Unit, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Università di Pavia, 21100 Varese, Italy., Fratamico RS; John and Dorothy Morgan Cancer Center, Lehigh Valley Cancer Institute, Allentown, PA 18103, USA., Russo C; Department of Medical Oncology, Centre Léon Bérard, Regional Comprehensive Cancer Centre, 69008 Lyon, France., Sbrana A; Pulmonary Oncology Unit, AOU Pisana, 56126 Pisa, Italy., Antonuzzo A; Medical Oncology 2, AOU Pisana, 56126 Pisa, Italy., Danova M; Department of Internal Medicine and Medical Oncology, ASST di Pavia, 27029 Pavia, Italy. |
| Abstrakt: |
Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy. |
